

1

2

## Electronic Supplementary Information (ESI)

3

4

### Biofunctional TiO<sub>2</sub> Nanoparticle Mediated Photokilling of Cancer

5

### Cells Using UV Irradiation

6

7 Kazusa Matsui<sup>1</sup>, Miki Karasaki<sup>1</sup>, Maiko Segawa<sup>1</sup>, Hwang Sang Youn<sup>2</sup>, Tsutomu Tanaka<sup>2</sup>,

8 Chiaki Ogino<sup>1\*</sup> and Akihiko Kondo<sup>1</sup>

9

10

11 <sup>1</sup>Department of Chemical Science and Engineering, Graduate School of Engineering,

12 Kobe University, 1-1 Rokkodaicho, Nada, Kobe 657-8501, Japan

13 <sup>2</sup>Organization of Advanced Science and Technology, Kobe University, 1-1 Rokkodaicho,

14 Nada, Kobe 657-8501, Japan

15

16

17 Corresponding author: Chiaki Ogino

18 Department of Chemical Science and Engineering, Graduate School of Engineering,

19 Kobe University, 1-1 Rokkodaicho, Nada, Kobe 657-8501, Japan

20 Tel/Fax: +81-78-803-6193

21 E-mail: ochiaki@port.kobe-u.ac.jp

22

23

#### 24 **Construction of Expression Plasmid**

25 KOD plus DNA polymerase (Toyobo) was used for PCR, and all PCR-amplified  
26 sequences were verified by DNA sequencing. The expression plasmid for  
27 anti-epidermal growth factor receptor (EGFR) antibody was constructed as follows: the  
28 gene encoding aEGFR VHH was obtained by PCR from genomic DNA of pUC-lal  
29 vector (Shishido, T.; Azumi, Y.; Nakanishi, T.; Umetsu, M.; Tanaka, T.; Ogino, C.;  
30 Fukuda, H.; Kondo, A.; *J. Biochem.* 2009, 46, 867-874) using the 5' primer  
31 (5'-AACCATGGCCCAGGTGCAGCTGCAGGAAAGCGGC-3') and 3' primer  
32 (5'-CTGAATTCCTAACCGCCAGTTTCCGGCAGAGAACCGCCATGGTGGTGATG  
33 ATGGTGCGAG-3'), and then subcloned into the *NcoI/EcoRI* sites of pET32b(+)  
34 (Novagen) to yield pET32b-la.

35

#### 36 **Expression and purification of anti-EGFR VHH**

37 Plasmid pET32b-la was transformed into *E. coli* BL21 (DE3) (Novagen). Cells were  
38 grown in LB medium to an OD (600 nm) value of 0.8, at which time expression of the  
39 protein was induced by the addition of isopropyl-b-D-thiogalactopyranoside (IPTG) at a  
40 final concentration of 0.5 mM. After growth for an additional 16 h at 27°C, the cells  
41 were harvested by centrifugation (15000 rpm, 4°C, 30 min). The cell pellets were  
42 resuspended in 50 mM NaPO<sub>4</sub> containing 300 mM NaCl (pH 7.0) and lysed by  
43 sonication. Anti-EGFR VHH was purified from the soluble fraction of the lysate by  
44 TARON metal affinity resins (Clontech) according to the manufacturer's protocol, and

45 dialyzed against 20 mM Tris-HCl containing 150 mM NaCl (pH 8.0). The concentration  
46 of purified anti-EGFR VHH was determined using a BCA protein assay kit (Pierce).

47

#### 48 **Preparation of polyacrylic acid (PAA)-modified TiO<sub>2</sub> nanoparticles**

49 Two kinds of acidic TiO<sub>2</sub> solution were purchased from Ishihara Sangyo Kaisha, Ltd.  
50 (Japan). The diameters of TiO<sub>2</sub> (STS-100) and TiO<sub>2</sub> (STS-01) are 10 nm 30 nm,  
51 respectively. A 1-ml aliquot of TiO<sub>2</sub> solution was mixed with 37.5 ml  
52 N,N-dimethylformamide (DMF), followed by 4 ml DMF containing 100 mg/ml PAA  
53 (average molecular weight: 5000, Wako Pure Chemical Industries, Japan) and incubated  
54 at 150°C for 5 h. After cooling the mixture to room temperature, twice volume of 99.5%  
55 acetone was added and the mixture was incubated at room temperature for 1 h to  
56 separate reacted TiO<sub>2</sub> nanoparticles. The precipitate was recovered by centrifugation  
57 (4,000 rpm, 20 min). Then 99.5% ethanol was added to supernatant for precipitation of  
58 PAA-modified TiO<sub>2</sub> and then centrifuged again. The precipitants were solubilized in 20  
59 mM HEPES buffer (pH 7.4).


60

#### 61 **Construction of anti-EGFR antibody-modified TiO<sub>2</sub> nanoparticles**

62 The PAA-TiO<sub>2</sub> suspension (6 w/v%, 2 ml) was gently mixed with 1 ml activating  
63 solution (80 mM 1-ethyl-3(3-dimethyl-aminopropyl)carbodiimide hydrochloride and 20  
64 mM N-hydroxy succinimide) and then incubated at room temperature for 1 h. The  
65 PAA-TiO<sub>2</sub> suspension was concentrated with Amicon Ultra-4 (Millipore). A centrifuged  
66 sample (1 ml) of the activated PAA-TiO<sub>2</sub> suspension was mixed with 1 ml of the

67 recombinant protein solution (approximately 2 mg/ml), and the mixture was incubated  
68 at 4°C overnight. Anti-EGFR antibody (Ia) was used as the homing molecule, and BSA  
69 (Sigma-Aldrich, St Louis, USA) was used as the control. Subsequently, 1.0 ml of 0.1 M  
70 ethanolamine solution was added to block activated carboxyl residues and the mixture  
71 was incubated at 4°C for an additional 30 min.

72



73

74

75 Figure S1. SDS-PAGE analysis of anti-EGFR antibody or anti-EGFR antibody  
76 (Ia)-modified TiO<sub>2</sub> nanoparticles. Lane 1: PAA-TiO<sub>2</sub>; lane 2: PAA-TiO<sub>2</sub> and anti-EGFR  
77 antibody mixtures; lane 3: PAA-TiO<sub>2</sub>/Ia


78

79 **Evaluation of the cell specific binding ability of anti-EGFR antibody-modified**  
80 **TiO<sub>2</sub> nanoparticles using ELISA**

81

82 HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Nacalai  
83 Tesque, Kyoto, Japan) containing 10% fetal bovine serum at 37°C under 5% CO<sub>2</sub>. Cells  
84 were grown in 96 well collagen coated 96 well plate (IWAKI Tokyo, Japan) with 2×10<sup>5</sup>  
85 cells/ml for 24 h. la, PAA-TiO<sub>2</sub> or PAA-TiO<sub>2</sub>/la particles were added into the wells and  
86 incubated additional 1h. After washing with serum-free DMEM three times, anti-6His  
87 rabbit polyclonal antibody (final concentration is 2 ng/ml; Bethyl laboratories) was  
88 added as a primary antibody. After incubation of 30 min, cells were washed as same  
89 way, then HRP labeled goat anti-rabbit IgG (final concentration is 2 ng/ml; GE  
90 healthcare) were added as secondary antibody. After further 30 min incubation, cells  
91 were washed three times, and the amount of binding la or PAA-TiO<sub>2</sub>/la was evaluated  
92 using ECL plus detection system (GE healthcare).

93



94

95 Figure S2 ELISA analysis of PAA-TiO<sub>2</sub>/la binding ability to cells.

96

### 97 Evaluation of TiO<sub>2</sub> and PAATiO<sub>2</sub> nanoparticle radical generation

98 2-[6-(4'-Amino)phenoxy-3*H*-xanthen-3-on-9-yl]benzoic acid (APF) (Sekisui Medical,  
99 Tokyo, Japan) was used to measure the amount of radicals generated from TiO<sub>2</sub> and  
100 PAA-TiO<sub>2</sub> nanoparticles by UV irradiation. These particles were dissolved in 20 mM  
101 HEPES buffer adjusted to 0.3, 0.03, 0.003, and 0.003 wt%. Then APF (10 mM) was  
102 added and UV irradiation was carried out using a UVB lamp (DNA-FIX, DF-312, Atto,  
103 Tokyo, Japan) with the peak at 312 nm. Fluorometric detection (ex. 495 nm and em. 515  
104 nm) of radicals was carried out using a Wallac ARVO 1420 multilabel counter (Wallac  
105 OY, Turku, Finland). Radical generation was averaged over at least three independent  
106 experiments.

107

### 108 Cytotoxicity assay

109 HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Nacalai  
110 Tesque, Kyoto, Japan) containing 10% fetal bovine serum at 37°C under 5% CO<sub>2</sub>. Cells  
111 were grown in 35-mm glass base dish (glass 12φ, Asahi Techno Glass Co., Tokyo,  
112 Japan) with 2×10<sup>5</sup> cells/ml for 24 h. PAA-TiO<sub>2</sub> or PAA-TiO<sub>2</sub>/Ia particles were added and  
113 UV irradiation was applied. After irradiation, cell viability was immediately (or after  
114 further 24 h incubation with DMEM containing 10% FBS) evaluated using a Live/Dead  
115 Viability/Cytotoxicity kit (Invitrogen, Carlsbad, CA). In brief, dishes were washed with  
116 PBS and then 150 μl PBS-combined Live/Dead assay reagents (0.1 mM calcein AM and  
117 2 mM EthD-1) were added. After incubation for 30 min at room temperature, the  
118 labeled cells were monitored under a fluorescence microscope (Keyence).